SPY334.89+2.52 0.76%
DIA277.50+3.08 1.12%
IXIC11,167.51+82.26 0.74%

Raymond James Initiates Coverage On ACADIA Pharmaceuticals with Outperform Rating, Announces Price Target of $65

Raymond James analyst Danielle Brill initiates coverage on ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform rating and announces Price Target of $65.

Benzinga · 08/25/2020 11:04
Raymond James analyst Danielle Brill initiates coverage on ACADIA Pharmaceuticals (NASDAQ: ACAD) with a Outperform rating and announces Price Target of $65.